These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34944843)

  • 1. Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy.
    Aleotti V; Catoni C; Poggiana C; Rosato A; Facchinetti A; Scaini MC
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
    Huang SK; Hoon DS
    Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
    Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
    Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant DNA methylation in malignant melanoma.
    Schinke C; Mo Y; Yu Y; Amiri K; Sosman J; Greally J; Verma A
    Melanoma Res; 2010 Aug; 20(4):253-65. PubMed ID: 20418788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy: current technology and clinical applications.
    Nikanjam M; Kato S; Kurzrock R
    J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.
    Micevic G; Theodosakis N; Bosenberg M
    Clin Epigenetics; 2017; 9():34. PubMed ID: 28396701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions.
    Pikturniene R; Cesas A; Jarmalaite S; Razbadauskas A; Urbonas V
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer.
    Mitchell SM; Ho T; Brown GS; Baker RT; Thomas ML; McEvoy A; Xu ZZ; Ross JP; Lockett TJ; Young GP; LaPointe LC; Pedersen SK; Molloy PL
    Genes (Basel); 2016 Dec; 7(12):. PubMed ID: 27983717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid Biopsies for Assessing Metastatic Melanoma Progression.
    Huynh K; Hoon DS
    Crit Rev Oncog; 2016; 21(1-2):141-54. PubMed ID: 27481010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives.
    Kanemaru H; Mizukami Y; Kaneko A; Kajihara I; Fukushima S
    Curr Treat Options Oncol; 2022 Apr; 23(4):562-577. PubMed ID: 35298769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Methylation Biomarkers for Characterization and Determination of the Cancer Origin in Malignant Liver Tumors.
    Draškovič T; Zidar N; Hauptman N
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.
    Wouters J; Vizoso M; Martinez-Cardus A; Carmona FJ; Govaere O; Laguna T; Joseph J; Dynoodt P; Aura C; Foth M; Cloots R; van den Hurk K; Balint B; Murphy IG; McDermott EW; Sheahan K; Jirström K; Nodin B; Mallya-Udupi G; van den Oord JJ; Gallagher WM; Esteller M
    BMC Med; 2017 Jun; 15(1):101. PubMed ID: 28578692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
    Aoude LG; Brosda S; Ng J; Lonie JM; Belle CJ; Patel K; Koufariotis LT; Wood S; Atkinson V; Smithers BM; Pearson JV; Waddell N; Barbour AP; Bonazzi VF
    J Mol Diagn; 2023 Oct; 25(10):771-781. PubMed ID: 37544359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
    Terp SK; Stoico MP; Dybkær K; Pedersen IS
    Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures.
    Al Hrout A; Levesque MP; Chahwan R
    Front Immunol; 2023; 14():1176175. PubMed ID: 37304281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors.
    Ravegnini G; Sammarini G; Serrano C; Nannini M; Pantaleo MA; Hrelia P; Angelini S
    Ther Adv Med Oncol; 2019; 11():1758835919831902. PubMed ID: 30854029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
    Moldogazieva NT; Zavadskiy SP; Terentiev AA
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.